Evolution of antibiotic treatments for healthcare-associated infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in France
| dc.rights.license | open | en_US |
| dc.contributor.author | LECURU, Marion | |
| dc.contributor.author | DANIAU, Come | |
| dc.contributor.author | ALFANDARI, Serge | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DUMARTIN, Catherine | |
| dc.contributor.author | BAJOLET, Odile | |
| dc.contributor.author | BLANCHARD, Herve | |
| dc.contributor.author | SIMON, Loic | |
| dc.contributor.author | ANNE-BERGER-CARBONNE | |
| dc.contributor.author | COLOMB COTINAT, Melanie | |
| dc.date.accessioned | 2022-10-28T09:27:44Z | |
| dc.date.available | 2022-10-28T09:27:44Z | |
| dc.date.issued | 2022-08-27 | |
| dc.identifier.issn | 2666-9919 (Electronic) 2666-9919 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/170135 | |
| dc.description.abstractEn | BACKGROUND: Infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) remain a public health challenge. AIM: We traced the evolution of antibiotics prescribed for patients with ESBLE-healthcare associated infections (ESBLE-HAI) between 2012 and 2017, with a specific focus on treatments for lower urinary tract infections (LUTI). METHODS: We used the 2012 and 2017 French point prevalence survey data. Patients with ESBLE-HAI were defined as those diagnosed with at least one Enterobacteriaceae with ESBL production. Patients with LUTI caused by ESBLE (ESBLE-LUTI) were defined as those with LUTI as the reported infection site and diagnosed with ESBLE. We only analysed treatments intended for HAI. RESULTS: In 2017, more than half of treatments for ESBLE-HAIs were β-lactams. While from 2012 to 2017 the proportion of carbapenem treatments decreased from 30% to 25%, penicillin treatments doubled. Among patients treated for ESBLE-LUTI, a larger proportion received a single antibiotic in 2017. The most frequently prescribed antibiotics for these infections were amoxicillin/clavulanic acid, nitrofurantoin and ofloxacin. More than one out of six treatments lasted for more than 7 days. Carbapenem use was halved between 2012 and 2017, and decreases were likewise observed for aminoglycosides. CONCLUSION: In accordance with French recommendations, comparison of the two most recent French point prevalence surveys showed an evolution in ESBLE-HAI treatment, especially for ESBLE-LUTI. However, treatment durations remained longer than recommended. Data from the 2022 survey should provide insights on the future evolution of prescription trends. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
| dc.subject.en | Enterobacteriaceae | |
| dc.subject.en | Extended-spectrum beta-lactamase | |
| dc.subject.en | Antibiotics | |
| dc.subject.en | Point prevalence survey | |
| dc.subject.en | Healthcare-associated infections | |
| dc.title.en | Evolution of antibiotic treatments for healthcare-associated infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in France | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.idnow.2022.08.003 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 36041699 | en_US |
| bordeaux.journal | Infectious Diseases Now | en_US |
| bordeaux.page | 396-402 | en_US |
| bordeaux.volume | 52 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 7 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03811746 | |
| hal.version | 1 | |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Infectious%20Diseases%20Now&rft.date=2022-08-27&rft.volume=52&rft.issue=7&rft.spage=396-402&rft.epage=396-402&rft.eissn=2666-9919%20(Electronic)%202666-9919%20(Linking)&rft.issn=2666-9919%20(Electronic)%202666-9919%20(Linking)&rft.au=LECURU,%20Marion&DANIAU,%20Come&ALFANDARI,%20Serge&DUMARTIN,%20Catherine&BAJOLET,%20Odile&rft.genre=article |
